176492-83-4

Basic information

• Product Name: N-(4-Ethylenedioxycylohexyl)-1-amino-2,2-diethoxyethane
• Synonyms: (2,2-DIETHOXY-ETHYL)-(1,4-DIOXA-SPIRO[4.5]DEC-8-YL)-AMINE;N-(4-ETHYLENEDIOXYCYLOHEXYL)-1-AMINO-2,2-DIETHOXYETHANE;N-(2,2-Diethoxyethyl)-1,4-dioxaspiro[4.5]decan-8-aMine
• CAS NO: 176492-83-4
• Molecular Formula: C₁₄H₂₇NO₄
• Molecular Weight: 273.36848
• Mol File: 176492-83-4.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-Ethylenedioxycylohexyl)-1-amino-2,2-diethoxyethane(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-Ethylenedioxycylohexyl)-1-amino-2,2-diethoxyethane(176492-83-4)
• EPA Substance Registry System: N-(4-Ethylenedioxycylohexyl)-1-amino-2,2-diethoxyethane(176492-83-4)

Safety Data

• Hazardous Substances Data: 176492-83-4(Hazardous Substances Data)

Usage

General Description

N-(4-Ethylenedioxycylohexyl)-1-amino-2,2-diethoxyethane is a chemical compound with the molecular formula C14H27NO3. It is a derivative of cyclohexylamine and diethoxyethane, containing an ethylenedioxy ring and an amine group. N-(4-Ethylenedioxycylohexyl)-1-amino-2,2-diethoxyethane has potential applications in organic synthesis, pharmaceutical research, and medicinal chemistry. Its properties and uses may include its role as a building block in the production of complex organic molecules, as well as its potential pharmacological effects due to its chemical structure and functional groups. Further research and testing are necessary to fully understand the properties and potential applications of N-(4-Ethylenedioxycylohexyl)-1-amino-2,2-diethoxyethane.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 645-36-3 2,2-diethoxy-ethanamine 
• 1184301-08-3 C₁₄H₂₅NO₄ 

Relevant articles and documents

Highly stereoselective synthesis of a compound collection based on the bicyclic scaffolds of natural products

Despite the great contribution of natural products in the history of successful drug discovery, there are significant limitations that persuade the pharmaceutical industry to evade natural products in drug discovery research. The extreme scarcity as well as structural complexity of natural products renders their practical synthetic access and further modifications extremely challenging. Although other alternative technologies, particularly combinatorial chemistry, were embraced by the pharmaceutical industry to get quick access to a large number of small molecules with simple frameworks that often lack three-dimensional complexity, hardly any success was achieved in the discovery of lead molecules. To acquire chemotypes beholding structural features of natural products, for instance high sp3 character, the synthesis of compound collections based on core-scaffolds of natural products presents a promising strategy. Here, we report a natural product inspired synthesis of six different chemotypes and their derivatives for drug discovery research. These bicyclic heteroand carbocyclic scaffolds are highly novel, rich in sp3 features and with ideal physicochemical properties to display drug likeness. The functional groups on the scaffolds were exploited further to generate corresponding compound collections. Synthesis of two of these collections exemplified with ca. 350 compounds are each also presented. The whole compound library is being exposed to various biological screenings within the European Lead Factory consortium.

Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne

The use of an interleukin β antibody is currently being investigated in the clinic for the treatment of acne, a dermatological disorder affecting 650M persons globally. Inhibiting the protease responsible for the cleavage of inactive pro-IL1β into active IL-1β, caspase-1, could be an alternative small molecule approach. This report describes the discovery of uracil 20, a potent (38 nM in THP1 cells assay) caspase-1 inhibitor for the topical treatment of inflammatory acne. The uracil series was designed according to a published caspase-1 pharmacophore model involving a reactive warhead in P1 for covalent reversible inhibition and an aryl moiety in P4 for selectivity against the apoptotic caspases. Reversibility was assessed in an enzymatic dilution assay or by using different substrate concentrations. In addition to classical structure-activity-relationship exploration, topical administration challenges such as phototoxicity, organic and aqueous solubility, chemical stability in solution, and skin metabolic stability are discussed and successfully resolved.

SUBSTITUTED N-CYCLOHEXYL IMIDAZOLINONES HAVING AN MCH-MODULATORY EFFECT

The invention relates to substituted N-cyclohexyl heterocycles as well as the physiologically acceptable salts and physiologically functional derivatives thereof, methods for the production thereof, and the use thereof as medicaments. Disclosed are compou